Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon’s separation from GSK created a consumer-health giant with dozens of power brands—and a web of disclosures that can overwhelm even seasoned analysts. Sales are broken out across oral care, pain relief, vitamins and more, while its first standalone Form 20-F runs hundreds of IFRS-heavy pages. If you have ever asked, "Where do I find Haleon insider trading Form 4 transactions" or "How do I decode Haleon’s quarterly earnings report 10-Q filing?", you know the challenge.
Stock Titan solves it. Our AI reads every new filing the moment it hits EDGAR, then delivers plain-English summaries, red-flags and searchable key terms. Whether you need Haleon Form 4 insider transactions in real-time, a side-by-side view of segment revenue from the latest 6-K, or want Haleon SEC filings explained simply, the platform highlights what matters: advertising spend trends, litigation provisions, post-spin debt covenants and more. Long-tail queries such as "Haleon executive stock transactions Form 4", "understanding Haleon SEC documents with AI", or "Haleon earnings report filing analysis" resolve to the exact section—no scrolling required.
All filing types are here, updated continuously: the Haleon annual report 10-K simplified (20-F), Haleon proxy statement executive compensation, and every Haleon 8-K material events explained. Use our tools to:
- Track insider buying and selling before marketing launches
- Compare vitamin and mineral supplement growth quarter-over-quarter
- Spot supply-chain disclosures in material event filings
Haleon plc (LSE/NYSE:HLN) announced PDMR notifications describing grants of share awards under its Share Value Plan and Performance Share Plan. The Performance Share Plan (Interim) awards vest in March 2028 subject to continued employment and performance conditions covering the period ending 31 December 2027; the relevant performance targets were disclosed in Haleon’s 2024 Annual Report and Form 20-F. The Share Value Plan (Buyout) awards are subject to continued employment. All awards were made in line with Haleon’s Directors' Remuneration Policy and are subject to malus and clawback provisions.
The filing discloses aggregate award volumes including items of 192,571 and 405,911 (shares/ADS) and notes that some volumes are Nil where applicable. No financial amounts, prices, or additional compensation details are provided in this report.
Haleon plc announced on 05 September 2025 that it purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,955,614,051 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,951,733,846 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company website. The announcement states it does not constitute an offer or solicitation in any jurisdiction.
Haleon plc reports the purchase and cancellation of 354,000 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,955,967,411 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,952,087,206 ordinary shares with voting rights. The announcement notes the trade venue (London Stock Exchange CBOE (UK)/CXE) and provides a link to a full breakdown of individual trades. The company also states this is not an offer for securities and that details are available on its investor website.
Haleon plc announced the purchase and cancellation of 2,900,000 ordinary shares under the second tranche of its share buyback programme. After settlement, the company’s registered share capital is 8,956,321,411 ordinary shares of £0.01 each, with 3,880,205 held as treasury shares, leaving 8,952,441,206 ordinary shares with voting rights. The company provided a link to a full breakdown of individual trades and noted the announcement does not constitute an offer for securities. The buyback transaction was executed on the London Stock Exchange and details are posted on the company website.
Haleon plc reported its total issued share capital and voting rights. The company has 8,959,221,411 ordinary shares of each, of which 3,880,205 are held in treasury, leaving 8,955,341,206 ordinary shares with voting rights. Shareholders and others with notification obligations should use the voting-rights figure as the denominator for FCA notification calculations and may send notifiable interests to [email protected]. The filing also provides a brief company description noting Haleon (LSE/NYSE: HLN) is a global consumer health company with major brands across Oral Health, VMS, Pain Relief, Respiratory, Digestive and Therapeutic Skin Health.
Haleon plc announces it purchased 2,062,463 ordinary shares of
Haleon plc reports the purchase and cancellation of 2,191,437 ordinary shares of each as part of the second tranche of its buyback programme announced 31 July 2025.
Trades executed on 28 August 2025 totalled 2,191,437 shares at prices reported on the London Stock Exchange/CBOE (UK)/CXE with an average indicative price shown in the announcement. After settlement, registered share capital is 8,961,283,874 ordinary shares, with 3,880,205 held in treasury, leaving 8,957,403,669 ordinary shares carrying voting rights. The company provides a link to a full breakdown of individual trades and notes the announcement is not an offer for securities. More details are available on the company website.
Haleon plc announces it purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,963,475,311 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,959,595,106 ordinary shares with voting rights. A full breakdown of the individual trades is provided via the linked RNS PDF and will also be available on the Company's investor website. The announcement clarifies it does not constitute an offer for securities.
Haleon plc announced the purchase and cancellation of 2,975,063 ordinary shares of each under the second tranche of its buyback programme announced 31 July 2025. The trades were executed on 26-27 August 2025 on the London Stock Exchange CBOE (UK)/CXE with individual trade prices reported and a weighted figure of 359.1984 shown in the announcement. After settlement the company's registered share capital is 8,966,351,142 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,962,470,937 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown and to the company's investor website for details.
Haleon plc announced the purchase and cancellation of 1,369,903 ordinary shares under the second tranche of its share buyback programme. The trades were executed on the London Stock Exchange/CBOE (UK)/CXE on 22 August 2025 and a full breakdown of individual trades is linked in the release. After settlement, the company's registered share capital is 8,969,326,205 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares, leaving 8,965,446,000 ordinary shares with voting rights. The announcement clarifies where the trade details and the announcement are available online.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
